Wen Guo1, Yingyun Gong2, Jie Li3, Pei Qin4, Jing Lu5, Xiaona Li6, Wenfang Zhu7, Nianzhen Xu8, Hongwen Zhou9, Qun Zhang10. 1. Department of Health Promotion Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, China. Electronic address: guowen20100305@126.com. 2. Department of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, China. Electronic address: gongyingyun@126.com. 3. Department of Endocrinology, Nanjing Central Hospital, Nanjing, 210018, China. Electronic address: black97450@126.com. 4. Department of Health Promotion Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, China. Electronic address: pqin1@ualberta.ca. 5. Department of Health Promotion Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, China. Electronic address: lj_123456@126.com. 6. Department of Health Promotion Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, China. Electronic address: 286696026@qq.com. 7. Department of Health Promotion Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, China. Electronic address: zhuwenfang216@126.com. 8. Department of Health Promotion Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, China. Electronic address: 15851877062@163.com. 9. Department of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, China. Electronic address: drhongwenzhou@njmu.edu.cn. 10. Department of Health Promotion Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, China. Electronic address: wenzi20100305@126.com.
Abstract
BACKGROUND AND AIM: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is rapidly gaining attention as a potential risk of developing atherosclerosis due to its crucial role in the regulation of low-density lipoprotein cholesterol (LDL-C) metabolism. The present study investigated the relationship between serum PCSK9 levels and early atherosclerosis as assessed by carotid intimal-medial thickness (CIMT) and brachial-ankle pulse wave velocity (ba-PWV) in newly diagnosed type 2 diabetes mellitus (T2DM). METHODS AND RESULTS: A total of 100 newly diagnosed T2DM were enrolled and further divided into the thickened CIMT group (n = 41) and the non-thickened CIMT group (n = 59) according to the results of color Doppler ultrasonography. Serum PCSK9 levels, CIMT, ba-PWV, and metabolic parameters were measured. Patients in the thickened CIMT group had higher serum PCSK9 levels than patients in the non-thickened CIMT group (all P < 0.05). CIMT and ba-PWV were both positively correlated to serum PCSK9 levels, while serum PCSK9 levels were positively correlated to white blood cell count, neutrophil, lymphocyte, and high-sensitivity C-reactive protein (P < 0.05). Multiple linear regression indicated that serum PCSK9 level was an independent predictor of CIMT (β = 0.637, P < 0.001) and ba-PWV (β = 0.600, P < 0.001). Binary logistic regression analysis showed that serum PCSK9 levels were independent risk factors of thickened CIMT [OR = 1.120, 95%CI (1.041-1.204), P = 0.002]. CONCLUSION: Serum PCSK9 levels are significantly correlated with CIMT and ba-PWV, independent of CAD risk factors. Therefore, serum PCSK9 level may have the potential to serve as a prescriptive biomarker for early arteriosclerosis in newly diagnosed T2DM.
BACKGROUND AND AIM: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is rapidly gaining attention as a potential risk of developing atherosclerosis due to its crucial role in the regulation of low-density lipoprotein cholesterol (LDL-C) metabolism. The present study investigated the relationship between serum PCSK9 levels and early atherosclerosis as assessed by carotid intimal-medial thickness (CIMT) and brachial-ankle pulse wave velocity (ba-PWV) in newly diagnosed type 2 diabetes mellitus (T2DM). METHODS AND RESULTS: A total of 100 newly diagnosed T2DM were enrolled and further divided into the thickened CIMT group (n = 41) and the non-thickened CIMT group (n = 59) according to the results of color Doppler ultrasonography. Serum PCSK9 levels, CIMT, ba-PWV, and metabolic parameters were measured. Patients in the thickened CIMT group had higher serum PCSK9 levels than patients in the non-thickened CIMT group (all P < 0.05). CIMT and ba-PWV were both positively correlated to serum PCSK9 levels, while serum PCSK9 levels were positively correlated to white blood cell count, neutrophil, lymphocyte, and high-sensitivity C-reactive protein (P < 0.05). Multiple linear regression indicated that serum PCSK9 level was an independent predictor of CIMT (β = 0.637, P < 0.001) and ba-PWV (β = 0.600, P < 0.001). Binary logistic regression analysis showed that serum PCSK9 levels were independent risk factors of thickened CIMT [OR = 1.120, 95%CI (1.041-1.204), P = 0.002]. CONCLUSION: Serum PCSK9 levels are significantly correlated with CIMT and ba-PWV, independent of CAD risk factors. Therefore, serum PCSK9 level may have the potential to serve as a prescriptive biomarker for early arteriosclerosis in newly diagnosed T2DM.
Authors: C Macchi; C Favero; A Ceresa; L Vigna; D M Conti; A C Pesatori; G Racagni; A Corsini; N Ferri; C R Sirtori; M Buoli; V Bollati; M Ruscica Journal: Cardiovasc Diabetol Date: 2020-11-03 Impact factor: 8.949